BioLife Solutions, Inc. (BLFS)
Stock Price:
$20.99 USD
-0.02 (-0.10%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
670.29M |
| Revenue (ttm) |
33.76M |
| Net Income (ttm) |
16.28M |
| Shares Out |
31.93M |
| EPS (ttm) |
0.87 |
| PE Ratio |
24.13 |
| Forward PE |
1,000.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$20.99 |
| Previous Close |
$21.01 |
| Change ($) |
-0.02 |
| Change (%) |
-0.10% |
| Day's Open |
21.00 |
| Day's Range |
20.72 - 21.13 |
| Day's Volume |
133,436 |
| 52-Week Range |
7.37 - 22.25 |
More Stats
| Market Cap |
670.29M |
| Enterprise Value |
665.04M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
31.93M |
| Float |
15.31M |
| EPS (basic) |
0.74 |
| EPS (diluted) |
0.87 |
| FCF / Share |
-0.13 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
4.14% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.13M |
| Short Ratio |
2.27 |
| Short % of Float |
4.22% |
| Beta |
1.52 |
| PE Ratio |
24.13 |
| Forward PE |
1,000.00 |
| P/FCF Ratio |
n/a |
| PS Ratio |
19.85 |
| PB Ratio |
9.12 |
| Revenue |
33.76M |
| Operating Income |
-354,000 |
| Net Income |
16.28M |
| Free Cash Flow |
-2.65M |
| Net Cash |
5.24M |
| Net Cash / Share |
0.16 |
| Gross Margin |
55.98% |
| Operating Margin |
-1.05% |
| Profit Margin |
48.20% |
| FCF Margin |
-7.84% |
| ROA |
0.89% |
| ROE |
71.05% |
| ROIC |
90.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
7 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$23.93*
(14.01% upside)
Low
21.0
Current: $20.99
High
26.0
Target: 23.93
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 27.37 | 19.74 | 11.02 | 8.23 | 6.45 | 6.19 | 8.95 | 5.66 | 2.76 | 2.08 |
| Revenue Growth | 38.64% | 79.11% | 33.97% | 27.57% | 4.17% | -30.83% | 58.03% | 105.28% | 32.53% | - |
| Gross Profit | 18.61 | 13.53 | 6.75 | 4.78 | 3.81 | 3.04 | 3.76 | 2.29 | 1.40 | 0.86 |
| Operating Income | -0.17 | 3.66 | -1.06 | -4.85 | -5.02 | -3.14 | -0.29 | -0.94 | -1.21 | -1.39 |
| Net Income | -1.66 | -25.01 | -2.52 | -6.88 | -4.21 | -3.22 | -1.08 | -1.66 | -1.96 | -1.98 |
| Shares Outstanding | 19.46 | 16.26 | 13.26 | 12.64 | 12.18 | 10.45 | 5.01 | 4.98 | 4.98 | 4.98 |
| Earnings Per Share | -0.09 | -1.56 | -0.21 | -0.54 | -0.35 | -0.31 | -0.22 | -0.33 | -0.42 | -0.42 |
| Operating Cash Flow | 1.21 | 2.35 | 0.61 | -4.33 | -4.97 | -3.16 | 0.15 | 0.85 | -0.99 | -1.25 |
| Capital Expenditures | -2.33 | -0.50 | -0.14 | -1.26 | -1.42 | -0.59 | -0.24 | -1.15 | -0.09 | -0.03 |
| Free Cash Flow | -1.12 | 1.85 | 0.46 | -5.58 | -6.39 | -3.75 | -0.09 | -0.30 | -1.08 | -1.28 |
| Cash & Equivalents | 6.45 | 30.66 | 6.66 | 1.41 | 3.82 | 9.94 | 0.16 | 0.20 | 0.02 | 0.00 |
| Total Debt | 1.35 | - | - | 2.84 | - | - | 10.60 | 10.60 | 10.13 | 9.03 |
| Net Cash / Debt | 5.09 | 30.66 | 6.66 | -1.44 | 3.82 | 9.94 | -10.45 | -10.41 | -10.11 | -9.03 |
| Assets | 92.82 | 45.47 | 12.14 | 7.93 | 12.37 | 16.07 | 3.35 | 3.17 | 1.66 | 1.31 |
| Liabilities | 49.36 | 30.84 | 2.05 | 4.76 | 2.51 | 2.14 | 16.62 | 15.66 | 12.84 | 10.86 |
| Book Value | 43.45 | 14.63 | 10.09 | 3.17 | 8.51 | 11.80 | -13.27 | -12.49 | -11.18 | -9.55 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
BioLife Solutions, Inc. |
| Country |
United States |
| CEO |
Michael P. Rice |
Stock Information
| Ticker Symbol |
BLFS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NASDAQ: BLFS |
| IPO Date |
November 22, 1989 |
Description
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; and liquid nitrogen laboratory freezers, cryogenic equipment, and accessories. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.